Lithium is a potent mood-stabilizing medication in bipolar disorder. Despite 50 years of clinical use, the mechanism of action is unknown. Multiple effects have been attributed to lithium including the uncompetitive inhibition of inositol monophosphatase (IMPase). IMPA2, one of the genes that encode IMPase, is located in a region with linkage to bipolar disorder. Owing to the role of IMPase in cell signaling and the possibility that this enzyme is a target for mood-stabilizing drugs, we generated IMPA2 À/À mice. 
INTRODUCTION
Bipolar disorder is a serious psychiatric disorder. It affects at least 1% of the population and is characterized by episodes of mania and depression (Goodwin and Jamison, 1990) . Notwithstanding the devastating impact, the underlying pathophysiology is still unknown. Lithium has been the standard pharmacological treatment for bipolar disorder over the last 50 years (Goodwin and Jamison, 1990) . In vivo and in vitro studies demonstrated that lithium exerts multiple effects on neurotransmitter/receptor-mediated signaling, ion transport, signal transduction cascades, hormonal and circadian regulation, and gene expression (for a review, see Jope (1999) and Quiroz et al (2004) ). At therapeutically relevant concentrations, it inhibits a group of at least four related phosphomonoesterases (inositol monophosphate phosphatase, inositol polyphosphate phosphatase, fructose 1,6-bisphosphate 1-phosphatase, and bisphosphate nucleotidase), the metabolic enzyme phosphoglucomutase, and glycogen synthase kinase-3 (GSK3). Despite 50 years of clinical use and despite intensive research, the precise mechanism by which lithium exerts its therapeutic effects is still unknown. A heuristic hypothesis proposed to explain lithium's mechanism of action is the inositol depletion hypothesis (Berridge et al, 1989) , which suggests that uncompetitive inhibition of inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase (IPPase) by therapeutically relevant lithium concentrations leads to an accumulation of inositol phosphates and a corresponding depletion of free myo-inositol. The consequent reduced rate of re-synthesis of phosphoinositide second messenger signal generation attenuates the response to neurotransmission. Valproic acid and carbamazepine, two other mood-stabilizing drugs, also cause depletion of free myo-inositol in rodent brain and in neuronal cells in vitro (Shaltiel et al, 2004; Williams et al, 2002) , thereby indicating that alterations in phosphatidylinositol-cycle activity may indeed play an important role in the pathophysiology and/or treatment of bipolar disorder.
IMPase is a key enzyme in the phosphatidylinositol signaling system. Two human genes encoding for IMPase (IMPA genes) have been cloned. The IMPA1 gene was found on chromosome 8q21.13-21.3 (Sjoholt et al, 1997) and IMPA2 was located on chromosome 18p11.2 (Sjoholt et al, 2000; Yoshikawa et al, 2000 Yoshikawa et al, , 1997 . Several studies have indicated the presence of a susceptibility locus for bipolar disorder on chromosome 18p (Berrettini et al, 1994; Rojas et al, 2000) . Sjoholt et al (2004) reported an association between bipolar illness and single-nucleotide polymorphisms in the promoter of IMPA2. Yoon et al (2001) reported that B lymphoblast cell lines derived from male bipolar patients exhibit downregulation of IMPA2 expression accompanied by high free intracellular Ca + 2 concentration. Subconvulsive doses of the cholinergic agonist pilocarpine induce limbic seizures in rodents pretreated with lithium (Honchar et al, 1983) . Lithium by itself does not have proconvulsant effects in rodents. Induction of lithiumpilocarpine seizures results in a drop in cortical inositol and elevation of inositol monophosphate levels. The reversal of lithium's effect by inositol provided behavioral support for the inositol depletion hypothesis .
Owing to the important role of IMPase in cell signaling, in general, and the possibility that this enzyme is a target for mood-stabilizing drugs, we used a retrovirus-mediated gene trap strategy to generate IMPA2 À/À mice. The present study describes molecular, biochemical, behavioral, and pharmacologic findings in IMPA2 À/À mice.
MATERIALS AND METHODS

Generation of IMPA2 À/À Mouse
The IMPA2 À/À mouse was generated by Lexicon Genetics Incorporated (The Woodlands, TX) using a gene trapping method. This approach disrupts gene function through the introduction of heterologous splice acceptor and splice donor sites that disrupt normal splicing of the trapped gene (Zambrowicz and Friedrich, 1998) . The gene trap integration site is determined by 3 0 rapid amplification of cDNA ends (RACE) followed by sequencing analysis. Today sequences of over 270 000 gene-trapped ES cell clones have been deposited into a searchable database (http://www. lexicongenetics.com/omnibank/overview.php). By searching the Lexicon Genetics database, we identified an 129Sv/Evbrd ES cell clone (Omnibank number OST 203987) containing a gene trap insertion, which is located in the first intron of the IMPA2 gene (Figure 1 ). 129Sv/Evbrd ES cell clones containing this insertion were injected into blastocysts to produce chimeric mice that were bred to C57BL/6J mice (1 generation) for germline transmission of the targeted allele. The resulting heterozygous animals were subsequently crossed to generate all three genotypes. Background effects were minimized by using mice with the same variation in genetic background. PCR was used to screen genotypes from DNA isolated from mouse tail biopsy samples. Primers 5 0 CTACAGCGGGAGGAGGTTTGCATGG-3 0 and 5 0 -TTCCTCCTAACTCGGGTCTGTGC-3 0 amplified a 376 bp band from the wild-type allele, whereas primers 5 0 AAATGGCGTTACTTAAGCTAGCTTGC-3 0 and 5 0 -TTCC TCCTAACTCGGGTCTGTGC-3 0 amplified a 228 bp band from the knockout allele.
Measurement of Gene Expression
To assess the effect of the trapping event, IMPA2 and IMPA1 expression was investigated using quantitative RT-PCR in several tissues of IMPA2 + / + , IMPA2 + /À , and IMPA2 À/À mice. Total RNA was isolated from different tissues using Trizol (Invitrogen; Carlsbad, CA) and firststrand cDNA synthesis was performed on 0.5 mg total RNA using random hexamer primers and SuperscriptII RT (Invitrogen; Carlsbad, CA). Quantitative PCR was performed on a ABIPrism 7700 cycler (Applied Biosystems; Foster City, CA) using a Taqman PCR kit. Serial dilutions of cDNA were used to generate standard curves of threshold cycles vs the logarithms of concentration for b-actin and IMPA2 and IMPA1. A linear regression line calculated from the standard curves allowed the determination of transcript levels in RNA samples from the mice. Specific sets of primer-probe pairs were used to assay expression levels (Table 1) .
IMPase Activity
IMPase activity was measured in tissue from 17-to 19-week-old IMPA2 + / + , IMPA2 + /À , and IMPA2 À/À male mice (n ¼ 10 per genotype). Tissue was divided in two. One half was used to measure IMPase activity; the other half was used to determine inositol levels. Hippocampus, frontal cortex, and kidney specimens were diluted (1 mg tissue/ 81 ml homogenization buffer (50 mM Tris-HCl pH 8.5, 150 mM KCl, 0.5 mM EDTA, and 0.1 mM EGTA)). Tissue samples were sonicated for 10 s, 41C at 50% power capacity (Heat System Ultasonic Inc.). The reaction mixture (final volume 105 ml) contained the following components: 40 ml homogenization buffer, 45 ml reaction buffer (50 mM TrisHCl pH 7.8, 250 mM KCl, and 3 mM MgCl 2 ), 5 ml inositol-1-phosphate 0.7 mM, and 5 ml crude homogenate. Each experiment included a standard curve of Pi (0-6 nmol). In Lithium-like effects in IMPA2 knockout mice K Cryns et al order to distinguish IMPase activity from nonspecific phosphatases, the reaction was carried out in the presence and absence of 30 mM lithium chloride (LiCl). LiCl is a specific inhibitor of this enzyme (Atack et al, 1995) and at these concentrations totally inhibits IMPase activity. Incubation was carried out for 30 min at 371C. The reaction was stopped by mixing with 100 ml color reagent. 
Gas Chromatographic Measurement of Inositol Levels
Mouse hippocampus, frontal cortex, and kidney specimens free inositol levels were analyzed as trimethylsilyl derivatives by gas chromatography, as previously described (Shapiro et al, 2000) with minor modification. Samples of tissue were extracted in 0.5 ml of boiling water containing 400 mg mannitol for 5 min, the denatured tissue was centrifuged (1000 g, 10 min, 41C), and 250 ml supernatant were lyophilized (3 h, Speed Vac SC 110); silylation of the dried sample was carried out with 200 ml of a mixture of pyridine: bis-(trimethylsilyl)-trifluoroacetamide:chlorotrimethylsilan 10 : 2 : 1 (vol/vol/vol) for 24 h at room temperature. In total, 1 ml of aliquots was chromatographed on a capillary column (RTX-1, 15 m, 0,25 mm ID, Restek), using a Chrompack gas chromatograph with a hydrogen flame ionization detector. The oven temperature was 150-2201C with rise of 101/min and the carrier gas was nitrogen with a flow of 30 ml/min. The TMS derivatives of mannopyranoside and myo-inositol had retention times of 3.5 and 6.3 min, respectively. Under these conditions, quantitation was performed with the use of TMS derivatives of standard myo-inositol under the same conditions and with mannopyranoside as an internal standard. Open field test. Locomotor activity was monitored using a Tru-scan r system (Coulbourn instruments, Allentown, USA). The animal was placed in the center of the activityfield arena, which is a transparent Perspex cage (W Â D Â H; 260 Â 260 Â 400 mm) equipped with two photo-beam sensor rings to register horizontal and vertical activity. 
Lithium-like effects in IMPA2 knockout mice K Cryns et al field/total distance traveled, in %) were analyzed as a measure for anxiety-like behavior.
Elevated zero-maze. The zero-maze consisted of an annular runway (diameter: 50 cm, width: 5 cm), elevated 50 cm above the floor. The maze was divided in four parts, that is, two opposite open parts and two opposite closed parts. The sidewalls of the opposing closed parts had a height of 20 cm; the open parts had borders with a height of 3 mm. The maze was enclosed by a black cabinet (size: 150 cm high by 132 cm wide). Light intensity on the open arms was 10 Lux and on the closed arms 2 Lux. All the animals were placed in the same start position, just in front of the opening of the closed part, facing the closed part. The animals were allowed to freely explore the maze for 5 min and their behavior was recorded and analyzed using the Ethovision Pro video tracking system (Noldus, The Netherlands). The software was capable of measuring the distance traveled and the time spent in each part of the maze. Three IMPA2 + / + and 1 IMPA2 À/À male mice were excluded from the analysis because they fell off the maze during testing.
TST. Mice were suspended by their tail to a hook in a test chamber using adhesive tape. Total duration of immobility was measured over a period of 6 min using the Videotrack system (Viewpoint, France). The Videotrack system was validated in-house with standard antidepressant compounds. For both mouse panels, one IMPA2 + / + and two IMPA2 À/À mice were excluded for analysis because the mice curled up towards their tail or fell off during testing.
Forced swim test. Mice were placed in a cylinder (diameter 10 cm), filled with water to a height of 10 cm (such that the mouse could not touch the bottom or rim of the cylinder at any point) and a temperature of 25711C. Each mouse was pre-exposed to swim-stress for 6 min on day 1 and a test session of 6 min was performed 24 h later. Total duration of immobility was measured using the Videotrack system (Viewpoint, France). The Videotrack system was validated in-house with standard antidepressant compounds.
Measurement of ACTH and CORT after Forced Swim Testing
Plasma adrenocorticotrophic hormone (ACTH) and corticosterone (CORT) levels were measured in 21-to 32-weekold male and female mice (n ¼ 6 for both female IMPA2 + / + and IMPA2 À/À mice, n ¼ 9 and 7 for male IMPA2 + / + and IMPA2 À/À mice, respectively). Animals were brought under light ether anesthesia and trunk blood was collected in EDTA blood collection tubes (Microtainer EDTA, Becton Dickinson, Switserland). All tubes were kept on ice and then centrifuged at 1090 g for 5 min at 41C. Separated plasma was frozen at À701C for subsequent ACTH or CORT determination (both in duplicate) using the RSL 125 I ACTH radioimmunoassay (RIA) kit and ImmuChemt double antibody CORT 125 I kit from MP Biomedicals (USA) following the manufacturer's protocol. ACTH and CORT levels were expressed in pg/ml and ng/ml plasma, respectively. In a subsequent experiment, ACTH and CORT levels were measured in 10-to 18-week-old IMPA2 + / + and IMPA2 À/À female littermates after forced swim testing (n ¼ 12 and 11 for IMPA2 + / + and IMPA2 À/À , respectively). Mice were subjected to forced swim testing once only for a total duration of 6 min. At 10 min after the forced swim test, animals were brought under light ether anesthesia and trunk blood was collected in EDTA blood collection tubes (Microtainer EDTA, Becton Dickinson, Switserland). ACTH and CORT levels were measured as described above.
Pharmacologic Studies
Amphetamine-induced locomotor activity. The effect of damphetamine on locomotor behavior was evaluated in
, and IMPA2 À/À male littermates with age ranging from 15 to 32 weeks. d-Amphetamine was dissolved in saline. Locomotion was evaluated in the Truscan r system (Coulbourn instruments, Allentown, USA). Mice were initially placed into the activity monitor chamber for 1 h, then injected i.p. with vehicle (10 ml/kg of body weight; n ¼ 9, 10, 7 for IMPA2 + / + , IMPA2 + /À , and IMPA2
, and IMPA2
À/À
, respectively, or 2 mg/kg, n ¼ 10, 10, 9 for IMPA2 + / + , IMPA2 + /À , and IMPA2 À/À , respectively). After the injection, the animals were returned to the activity-field arena and monitored for 2 h (in 5-min time-bins).
Pilocarpine-induced seizures. IMPA2
+ / + and IMPA2 À/À male littermates (18-22 weeks old) were injected subcutaneously (s.c) with 100 or 200 mg/kg pilocarpine (n ¼ 5 for each dose) and rated for signs of seizures once every 5 min for 2 h according to a modified version of the scale used by Patel et al (1988) . The scoring was as follows: 0 ¼ no response; 1 ¼ gustatory movements and/or fictive scratching; 2 ¼ tremor; 3 ¼ head bobbing; 4 ¼ forelimb clonus; 5 ¼ rearing, clonus and falling. In addition, the latency to attain rearing, clonus, and falling (a score of 5) was recorded for each mouse . A welltrained blind observer scored the mice. To further study the possibility of lithium augmentation to reveal pilocarpine sensitivity of the IMPA2 À/À mice, we pretreated IMPA2 + / + and IMPA2 À/À male littermates with 3 meq/kg (n ¼ 5) and 6 meq/kg (n ¼ 5) lithium. 
Statistical Analysis
The Kolmogorov-Smirnov test was used to evaluate the normality assumption of expression data, behavioral data, and CORT and ACTH data after forced swim stress. Expression data, behavioral data, and CORT and ACTH data after forced swim stress were analyzed using a Student's t-test or a Mann-Whitney Rank Sum Test in case of data that were not normally distributed. A one-way ANOVA was used to compare IMPase activity and inositol levels between the different genotypes. Parametric statistical analysis was chosen based on our previous data of these assays (Motulsky, 1995) .
To evaluate rearing before amphetamine administration, a one-way ANOVA was used. A two-way ANOVA (genotype Â treatment) was used to assess the effect of amphetamine treatment on locomotor behavior and rearing in the open field test and of lithium on immobility in the forced swim test. A two-way ANOVA (gender Â genotype) was also used to analyze CORT and ACTH data in baseline conditions. Residual plots were used to diagnose the appropriateness of the final ANOVA models used. This graphical examination included histograms, QQ-plots, and plots of residuals vs fitted values. No departures from the ANOVA assumptions were detected. In case data were not normally distributed, a log e transformation was performed. A Fisher's exact test was used to evaluate the effect of acute lithium treatment.
RESULTS
IMPA2 and IMPA1 Expression
IMPA2 expression was found to be completely abolished in IMPA2 À/À mice, indicating that the trapping event resulted in a null allele of IMPA2 (Figure 2) .
To look for potential compensatory mechanisms, IMPA1 mRNA levels were analyzed in brain and liver tissue from Inositol levels and IMPase activity were also compared in the kidneys, which is the tissue with the highest expression of IMPA2 (Figure 2 ). Reduced IMPA2 gene-dose resulted in a significant reduction in inositol levels (23% in IMPA2 25.00 Table 3a and b summarize the behavioral data for male and female IMPA2 KO mice, respectively. General locomotor and exploratory behavior was assessed in the open field. The distance traveled and the total time in motion was comparable between IMPA2 À/À male mice and control mice. In contrast, in female IMPA2 À/À mice, the distance traveled and the total time in motion was significantly higher compared to IMPA2 + / + female mice. Both in male and female mice, there was no difference between genotypes in the relative distance traveled in the center. However, the relative time spent in the center of the open field was Lithium-like effects in IMPA2 knockout mice K Cryns et al significantly higher in male IMPA2 À/À mice but not in female IMPA2
Behavioral Analysis
À/À mice. In addition, a borderline significantly increased number of rearings was observed in both male and female IMPA2 À/À mice. In the elevated zero-maze, anxiety-related behavior was evaluated by measuring the relative time spent and distance traveled in the open areas. Measures were not altered in male and female IMPA2 À/À mice. Similarly, analysis of locomotion on the elevated zero-maze revealed no differences between the two genotypes tested in male and female IMPA2 À/À mice. Depression-related behavior was assessed in the tail suspension and in the forced swim test. As summarized in Table 3a , male IMPA2 À/À mice did not exhibit a difference in total immobility time in the tail suspension test or in the forced swimming test. Female IMPA2 À/À mice also did not exhibit a difference in total immobility time in the tail suspension test but in the forced swim test total immobility time was significantly lower compared to control mice.
Measurement of Plasma ACTH and CORT after Forced Swimming
ACTH and CORT levels are presented in Table 4 . At baseline condition, no genotype effect was seen on ACTH (F (1,24) ¼ 2.69, p ¼ 0.11) and CORT levels (F (1,24) ¼ 0.45, p ¼ 0.51). There was a significant difference in ACTH levels between male and female mice (F (1,24) 
Pharmacologic Studies
Amphetamine-induced locomotor activity. Locomotor behavior of IMPA2 + / + , IMPA2 + /À , and IMPA2 À/À mice in the open field test was evaluated after d-amphetamine administration. Before drug administration, a significant genotype effect on the number of rears was seen (F (2, 85) ¼ 3.92, p ¼ 0.0235, Figure 3a) . Post hoc testing indicated rearing was significantly increased in IMPA2 À/À animals compared to IMPA2 + /À mice (p ¼ 0.04). A tendency for an increase in rearings was seen in IMPA2 À/À compared to IMPA2 + / + mice (p ¼ 0.062). Baseline locomotor activity as measured by total distance traveled before drug administration was not different between the three genotypes (F (2,84) ¼ 2.209, p ¼ 0.116, Figure 3b ). Amphetamine administration produced a significant increase in total distance traveled (drug effect, F (2,73) ¼ 49.65, po0.0001, Figure 3c ), but no effect of genotype was observed (F (2,73) ¼ 1.53, po0.223). Post hoc analysis indicated that animals treated with 1 and 2 mg/kg travelled significantly more than control treated animals (po0.0001 for both doses). There was no genotype Â drug interaction (F (4,73) 
Detailed analysis of locomotor activity over time confirmed the absence of a genotype and genotype Â drug interaction effect on the total distance traveled (data not shown). Amphetamine treatment resulted in a significant increase in the number of rears (F (2,73 Injection of 100 mg/kg pilocarpine has previously been shown to induce limbic seizures in mice pretreated with 10 meq/kg lithium (Bersudsky et al, 1994) . As a positive control, 100 mg/kg pilocarpine following 10 meq/kg lithium were injected to IMPA2 À/À and IMPA2 + / + mice. As expected, limbic seizures in both groups were observed with no difference in latency to clonus and seizure score between the two groups of mice. Table 5 . IMPA2 À/À mice did not show a different sensitivity to LiClinduced lethality compared to IMPA2 + / + mice.
Effect of chronic lithium treatment on the forced swim test. IMPA2 + / + , IMPA2 + /À , and IMPA2 À/À mice were subjected to forced swim testing following chronic lithium treatment. A two-way ANOVA revealed a significant effect of treatment (F (2, 112) ¼ 5.377, p ¼ 0.006) on immobility time (Figure 4) . Post hoc analysis indicated that animals treated with 0.4% lithium carbonate showed reduced immobility time in the forced swim test (p ¼ 0.012) compared to mice treated with control chow. No effect of genotype (F (2,112) ¼ 0.0429, p ¼ 0.958) or a genotype Â treatment interaction was observed (F (4,112) 
DISCUSSION
Inositol is a cyclic polyol that forms the backbone of important intracellular signaling molecules. Therefore, profound effects on the cell can be expected if one interferes with inositol formation. Interestingly, lithium, valproic acid, and carbamazepine are three drugs with mood-stabilizing properties that decrease myo-inositol levels (for a review, see Harwood, 2005) . Based on these observations, inositol depletion was proposed as a therapeutic mechanism in the treatment of bipolar disorder (Berridge et al, 1989) . IMPase is a key enzyme in establishing this depletion in the case of lithium. The inositol depletion hypothesis has been the subject of much debate and current data are neither convincing in favor of, nor eliminate the possibility of this hypothesis. In the present work, we phenotyped IMPA2 À/À mice showed a small (9.5%) but significant decrease in immobility time in the forced swim test. A significant increase in the total time in motion and the total distance traveled in the open field test was also observed in female IMPA2 À/À mice while these parameters were unaltered in male IMPA2 À/À mice. Therefore, the aberrant behavior of female IMPA2 À/À mice in the forced swim test most likely reflects an increased locomotor behavior rather than an antidepressant phenotype. Interestingly, a different depressive phenotype in male vs female mice has also been shown in 5HT knockout mice (Jones and Lucki, 2005) . There was no difference between male and female IMPA2 À/À and IMPA2 + / + mice in the tail suspension test, overall suggesting no effect of the deletion of the IMPA2 gene on the depression-like behavior.
A trend towards an increased number of rears in the open field was observed in male and female IMPA2 À/À mice monitored for 30 min. This trend reached significance in a third mouse panel monitored for 60 min (prior to amphetamine administration), suggesting an increased exploratory behavior. Kofman et al (1991) reported reduced rearing in lithium-treated mice, an effect reversed by inositol administration, and enhanced rearing following dietary inositol load (Kofman et al, 1998) . Thus, it may have been expected that IMPA2 À/À mice would show reduced rearing as a lithium-like effect. Counterintuitively, an enhancement was observed. Interestingly, it has recently been shown that mice treated with the antidepressant fluoxetine at an early postnatal age (pd 4-pd 20) demonstrate depressive-and anxiety-like behaviors at adulthood in contrast with the antidepressant and anxiolytic effects of SSRIs when administered at an adult age (Ansorge et al, 2004) . In parallel, it may be that lifelong reduction in IMPA2 levels affects rearing differently than chronic lithium treatment of adult mice.
In À/À and wild-type mice in the relative time spent in the center, no difference was seen when data were analyzed in 5 min time-bins (data not shown), that is, for neither parameter a genotype effect was seen during the first 10 min of the test session. This would suggest that IMPA2 À/À mice show increased exploratory behavior rather than an anxiolytic phenotype.
CORT and ACTH levels were measured in male and female IMPA2 + / + and IMPA2 À/À mice. No significant effect of genotype or a genotype Â gender interaction was seen on CORT and ACTH levels. ACTH levels were significantly different between male and female mice, whereas CORT levels were not different between both genders. It should be noted that gender differences in HPA-axis activity have been well demonstrated by others (eg Timpl et al, 1998) . In a subsequent experiment, it was shown that female IMPA2 À/À mice did not show altered stress-hormone levels compared to female IMPA2 À/À mice after forced swim stress, thereby suggesting that IMPA2 is not involved in modulation of the HPA axis.
Amphetamine is an indirect dopamine-receptor agonist as it elevates extracellular dopamine levels in mouse striatum. Hyperlocomotion in the open field test after damphetamine administration is considered to be an animal model for mania (Einat and Belmaker, 2001) , and lithium salts are reported to antagonize this behavior (Einat and Belmaker, 2001) . Amphetamine clearly induced hyperlocomotion as measured by a significant increase in the distance traveled, but no effect of genotype or a genotype Â drug interaction was observed, indicating that IMPA2 À/À mice do not differently respond to amphetamine-induced manic-like behavior.
To study the possible involvement of the IMPA2 gene in the molecular mechanism of lithium's inhibitory effect on IMPase, we used the behavioral paradigm of lithiumpilocarpine seizures. It has been suggested that brain inositol depletion due to IMPase inhibition is critical to the development of lithium-pilocarpine-induced seizures . We therefore hypothesized that IMPA2 À/À mice would present a lithium-like effect in this paradigm. No limbic seizures were observed in IMPA2 À/À mice following subconvulsive pilocarpine doses. These data suggest that the IMPA2 gene does not significantly contribute to brain IMPase activity and therefore knocking it out is not enough to mimic this behavioral effect of lithium. The fact that we did not find inositol depletion or reduced IMPase activity in the frontal cortex and in the hippocampus of IMPA2 À/À compared with IMPA2 + / + mice is consistent with this conclusion. Chronic lithium treatment resulted in a significant reduction in immobility time but no genotype or genotype Â treatment interaction was seen, indicating lack of augmentation effect of IMPA2 knockout on the antidepressant effect of lithium in the forced swim test (O'Brien et al, 2004) . It should be noted that the reduction in immobility time was only observed in the animals treated with food containing 0.4% lithium. This treatment regime results in lithium plasma levels that are higher than the therapeutic range in humans (data not shown). Furthermore, mice from the 0.4% group showed a reduction in body weight (data not shown), which might interfere with their behavior. Therefore, the reduction in immobility time should be interpreted cautiously.
Among tissues studied, IMPA2 expression is highest in kidney. We therefore studied the effect of IMPA2 À/À on IMPase activity and inositol levels in this tissue. We did find a gene-dose effect on kidney inositol levels in the IMPA2 À/À mice raising the possibility that the IMPA2 gene is involved in renal side effects of lithium treatment. Bersudsky et al (1992) have previously reported that lithium-treated rats that drank inositol solution developed polydipsia much slower than rats drinking mannitol solution.
Altogether our results indicate that deletion of the IMPA2 gene did not resemble the pharmacological effects of lithium. Gene targeting to create null mutations in mice is a powerful tool to study complex phenotypes and assessing how genes influence biological functions in vivo. Yet, if a KO mouse does not exhibit a phenotypical change it maybe due to compensatory effects of other genes. However, no difference in brain or liver IMPA1 expression levels was found between IMPA2 À/À and IMPA2 + / + mice ruling out the possibility that the lack of phenotypical changes in IMPA2 À/À mice results from a compensatory upregulation of the IMPA1 gene. In this context, it is also not conceivable that the 24% increase in hippocampal IMPase activity in the IMPA2 À/À mice is responsible for the lack of phenotypical changes as our assay measures the V max of the enzyme, whereas in vivo a much lower enzyme rate is physiologically sufficient.
It is noteworthy that the effectiveness of inositol depletion will also depend on influx of inositol from exogenous sources. In the brain, there are two myo-inositol transporters. SMIT (sodium/myo-inositol transporter) is dependent on Na + and inhibited at reduced pH (Hager et al, 1995) . The second transporter is HMIT (H + /myo-inositol transporter), which is activated as the pH lowers. After depolarization and activation of protein kinase C (PKC), HMIT is translocated to the plasma membrane at growth cones, leading to an increased myo-inositol uptake (Uldry et al, 2004) . Interestingly, gene expression profiling indicated that PKCe and PKCi are both upregulated in hippocampus of IMPA2 À/À mice (data not shown). This upregulation may lead to an increased exogenous inositol uptake via HMIT, thereby compensating for the inositol depletion. Alternatively, absence of a lithium-like phenotype in IMPA2 À/À mice may point to functional redundancy of IMPA2, potentially provided by IMPA1 (Cryns et al, 2005) . This is supported by the fact that the expression of IMPA1 is several fold higher than that of IMPA2 in mice and in human frontal cortex (Agam et al, 2002) .
In conclusion, molecular, behavioral, and pharmacologic analysis of the IMPA2 À/À mouse indicates that deleting the IMPA2 gene does not mimic the effects of lithium treatment. Compensatory mechanisms and/or functional redundancy may be responsible for the absence of depression-or mania-related phenotypes. To exhibit lithium-like behavioral and molecular effects, IMPA1 or both IMPase genes may have to be knocked out. Yet, even in SMIT À/À mice with the most severe inositol deficiency ever recorded in mammals, there is no significant loss of phosphatidylinositol (Berry et al, 2004) .
